Endometriosis Drug Significantly Reduces Pain in Trial
BANGALORE (Reuters) Jul 11 - Repro Therapeutics Inc. said its lead experimental drug Proflex significantly relieved pain in women suffering from endometriosis, a condition affecting the uterus, according to the interim analysis of a mid-stage trial.
Data showed that, compared with placebo treatment, Proflex significantly reduced pain, which is a key symptom associated with endometriosis, after 1 to 2 months of treatment, the company said in a statement. Trial investigators reported that the effect was clinically meaningful.
The company said the 25-mg and 50-mg doses of its drug were not significantly different in reducing pain, and that most side effects were mild.
Repro said the 50-mg dose of the drug was better at relieving pain than Abbott Laboratories’ Lupron – which is currently used to treat endometriosis, uterine fibroids and prostate cancer.